Document is current
Any future updates will be listed below
-
Authors
Duan, Yi
Chu, Huikuan
Brandl, Katharina
Jiang, Lu
Zeng, Suling
Meshgin, Nairika
Papachristoforou, Eleni https://orcid.org/0000-0003-1553-1405
Argemi, Josepmaria https://orcid.org/0000-0003-1696-7753
Mendes, Beatriz G.
Wang, Yanhan
Su, Hua
Sun, Weizhong
Llorente, Cristina https://orcid.org/0000-0001-8135-9186
Hendrikx, Tim
Liu, Xiao
Hosseini, Mojgan
Kisseleva, Tatiana
Brenner, David A.
Bataller, Ramon https://orcid.org/0000-0002-1119-7799
Ramachandran, Prakash https://orcid.org/0000-0001-5996-2413
Karin, Michael
Fu, Wenxian
Schnabl, Bernd https://orcid.org/0000-0002-6281-825X
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism (R01 AA024726, U01 AA026939)
U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism
- License Information
-
More Information
Article History
Received: 10 November 2020
Accepted: 15 November 2021
First Online: 9 December 2021
Competing interests
: B.S. has been consulting for Ferring Research Institute, Intercept Pharmaceuticals, HOST Therabiomics, Mabwell Therapeutics, Patara Pharmaceuticals and Takeda. B.S.’s institution UC San Diego has received grant support from BiomX, NGM Biopharmaceuticals, CymaBay Therapeutics, Synlogic Operating Company, Prodigy Biotech and Axial Biotherapeutics. B.S. is founder of Nterica Bio. UC San Diego has filed several patents with B.S. as inventor related to this work. The remaining authors declare no competing interests.
